Related Experiment Videos
Pharmacologic preservation of the hemostatic system during cardiac surgery
1Division of Cardiothoracic Anesthesiology and Critical Care, Emory University School of Medicine, Emory Healthcare, Atlanta, Georgia, USA. jerrold_levy@emoryhealthcare.org
Insights
Managing bleeding after cardiac surgery involves various pharmacologic strategies. These aim to reduce bleeding and transfusion needs by addressing cardiopulmonary bypass-induced coagulopathy and new anticoagulant challenges.
Area of Science:
- Cardiology
- Hematology
- Pharmacology
Background:
- Post-cardiac surgery bleeding is a significant clinical issue.
- Cardiopulmonary bypass (CPB) can induce coagulopathy, increasing bleeding risk.
- Managing coagulopathy is crucial for patient outcomes.
Purpose of the Study:
- To review pharmacologic approaches for managing bleeding after cardiac surgery.
- To discuss strategies for attenuating hemostatic system activation.
- To explore challenges posed by new anticoagulants and antiplatelet agents.
Main Methods:
- Review of therapeutic strategies targeting thrombin generation and platelet function.
- Analysis of agents preventing or reversing CPB-induced coagulopathy.
- Evaluation of established and emerging pharmacologic treatments for bleeding.
Main Results:
- Pharmacologic agents aim to inhibit thrombin, preserve platelet function, and reduce allogeneic transfusions.
- Aprotinin and lysine analogues are mainstays for bleeding prevention.
- Newer agents like recombinant activated factor VIIa show potential for refractory bleeding.
Conclusions:
- Effective management of cardiac surgery bleeding requires addressing coagulopathy.
- A range of pharmacologic interventions exist, from established agents to novel therapies.
- Optimizing hemostasis is key to improving patient safety and reducing transfusion dependence.
Abstract:
Bleeding after cardiac surgery remains a major potential problem. Numerous pharmacologic approaches to attenuating hemostatic system activation in cardiac surgery patients have been studied to further improve patient management. Therapeutic approaches studied include inhibiting thrombin generation or activation, preserving platelet function, and decreasing the need for transfusion of allogeneic blood products. Pharmacologic approaches to reduce bleeding and transfusion requirements in cardiac surgery patients are based on either preventing or reversing the defects associated with the CPB-induced coagulopathy. The increasing use of platelet inhibitors (clopidogrel and IIb/IIIa receptor antagonists) and new anticoagulants (low-molecular weight heparins, pentasaccharide, recombinant hirudin, bivalirudin, and argatroban) also pose interesting problems in managing cardiac surgery patients. Aprotinin and lysine analogues (epsilon-aminocaproic acid and tranexamic acid) have become mainstay therapeutic agents to prevent bleeding and the potential need for allogeneic transfusion. Newer therapies that are important to consider include the potential of recombinant activated factor VIIa as a therapy for refractory bleeding after cardiac surgery.